Estramustine Phosphateによる前立腺進行癌の治療

Abstract

Effects of estramustine phosphate (Estracyt/, EMP) were studied in 20 patients with •advanced carcinoma of the prostate. Ten patients received no treatment before EMP-therapy(study I), and the other 10 patients received previous estrogen-therapy (study II). Some of the latter cases showed resistance to estrogen-therapy immediately, and the others suffered relapses after varying periods of remission. In study I, EMP showed 75% .improvement of subjective symptoms (dysuria, urination frequency and pain), and 88% of objective signs (residual urine, palpation of the prostate and serum prostatic acid phosphatase). In study II, it showed 25% improvement of subjective symptoms and 60% of objective signs. Comprehensive evaluation showed that the effectiveness of EMP on prostatic carcinoma was 90% in study I, and 50% in study II. The effectiveness of EMP closely related to the duration of the remission elicited by preceding estrogen-therapy. In cases where the remission was less than 2 years, the effectiveness of EMP was 90-100%. However, if the remission was more than 2 years, it was only 17%. From these results, it was concluded that EMP should be administered as a first choice drug.